Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Vetjournal /     
 
Cox-2-expression in canine keratinocytes
Cyclooxigenase 2 (Cox-2) has been demonstrated to be overexpressed in various neoplasias in both animals and men, also in the canine squamous cell carcinoma, one of the most common skin tumours in dogs. This excellent article, a Swiss-Canadian cooperation, gives very interesting insights in the COX-2 expression of both normal and abnormal keratinocytes which may lead to improved therapeutic techniques in the following years.

Original Article
Expression and regulation of cyclooxygenase-2 in normal and neoplastic canine keratinocytes
N. Pronovost1, M. M. Suter2, E. Mueller2, J. Sirois3 and M. Doré1*
Squamous cell carcinoma (SCC) is one of the most common cancers in dogs, yet relatively little is known about the molecular events involved in its development.

Increasing evidence implicates cyclooxygenase-2 (COX-2) in the pathogenesis of various cancers in humans and animals. COX-2 overexpression has recently been demonstrated in canine SCCs.

The objective of our study was to characterize the expression and regulation of COX-2 in normal and neoplastic canine keratinocytes (CKs) to provide an in vitro system to investigate the implication of COX-2 in SCC oncogenesis in dogs.

Cell lines derived from normal CKs and neoplastic CKs (SCCs) were cultured in the absence or presence of agonists, and immunoblots, immunocytochemistry, radioimmunoassays and a cell proliferation assay were used to characterize COX-2 expression and action.

Results showed that neoplastic keratinocytes had a higher basal COX-2 expression than normal keratinocytes.
In both cell lines, stimulation with the tumour promoter phorbol 12-myristate 13-acetate induced a time-dependent increase in COX-2 protein, with COX-2 induction being stronger in cancerous SCC than in normal CK cells.
Moreover, SCC cells produced significantly more PGE2 than CK cells, under both baseline and stimulated conditions (P < 0.05). NS-398, a selective COX-2 inhibitor, inhibited prostaglandin (PG)E2 synthesis and decreased proliferation of CK and SCC cells (P < 0.05).

Collectively, our results indicate that the canine neoplastic keratinocyte SCC cell line expresses more COX-2 and produces more PGE2 than the normal keratinocyte CK cell line, thus providing an in vitro system to study the molecular basis of elevated COX-2 expression in SCCs in dogs.


Source: Pronovost, N., Suter, M. M., Mueller, E., Sirois, J. & Doré, M. (2004): Expression and regulation of cyclooxygenase-2 in normal and neoplastic canine keratinocytes. In: Veterinary and Comparative Oncology 2 (4), 222-233.




Tell a friend   |   Print version   |   Send this article

VETJOURNAL

VetAgenda

  • Join the 11th Eurasia Veterinary Conference at the island Zanzibar, Tansania 2018
  • Lab in Practice - Clinical Pathology
  • European Master of Small Animal Veterinary Medicine
  • SEVC 2014
  • ESAVS - Neuropathology & MRI
  • CongressMed 2014
  • ACVIM 2014
  • VetContact
  • WVEPAH Courses
  • Optimizing MRI results of the spinemembers
  • Garfield is turning back the clock


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved